Omnicell (OMCL) Piper Sandler 36th Annual Healthcare Conference summary

Strategic direction and product innovation

• Focus on expanding advanced services, including IV compounding, central pharmacy dispensing, inventory optimization, outpatient digital pharmacy, and specialty pharmacy, to drive future growth and revenue mix.

• XT Amplify platform introduced, featuring five initial products (XT Extend, MedChill, SupplyXpert, ServerScale, CarePlus) with more planned, targeting both hardware and software innovation.

• MedChill enables traceability and controlled access for refrigerated medications, addressing a key operational challenge in hospitals.

• XT Amplify aims to extend cabinet lifecycles and shift customer focus from hardware age to ongoing innovation and outcomes.

• Emphasis on deep EHR integration and digitization of medication management to improve safety, efficiency, and financial outcomes.

Market position and competitive landscape

• Holds 45% market share in ADCs, with 62% intent to buy among hospitals, outpacing the largest competitor.

• Customers prioritize long-term innovation and platform capabilities over short-term competitive disruptions.

• FDA warning letters to competitors seen as minor, with decision-making driven by strategic roadmaps and system integration.

Financial outlook and revenue drivers

• XT Amplify bookings available in 2024, with revenue contribution expected in 2025; will not offset ADC sales decline next year.

• Advanced Services revenue grew 23% year-over-year in Q3, led by specialty pharmacy services.

• XT Extend pricing aligns with historical console upgrades but offers additional upsell opportunities through bundled innovations.

• Multi-year agreements (5–10 years) are common with XT Amplify, supporting revenue linearity and customer retention.